Subjects were recruited from Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia. This took place from 01 November to 30 November 2019 under Ethics Approval Number 113/EA/FK-RSUDZA/2019, Fakultas Kedokteran Universitas Syiah Kuala Rumah Sakit Umum Daerah Dr Zainoel Abdin. All subjects were adults and gave written informed consent for study participation. These subjects all had active TB as defined by positive Ziehl-Neelsen staining of sputum and PCR test using GenXpert prior to treatment.

Two groups of subjects were studied: Active TB before treatment (n = 18), and a second group of previously Active TB subjects that were 8 weeks into treatment, and who had become negative on their Ziehl-Neelsen sputum staining (n = 18).

The treatment used on all subjects for anti-MTB therapy was rifampicin, isoniazide, ethambutol and pyrazinamide. Later follow up on the individuals of both groups found that they were cured after 24 weeks treatment, as defined by subjects showing clinical improvement and negative Ziehl-Neelsen staining.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.